

PHYSICIANS' CONCLAVE
ON
CONTROLLED HUMAN INFECTION STUDIES (CHIS)

Bringing together medical professionals & key stakeholders for establishment of CHIS



**FEBRUARY 15, 2025, 12:00PM ONWARDS** 



# Controlled Human Infection Study (CHIS) Facility at MRC, THSTI

#### What is CHIS?

Controlled Human Infection Studies (CHIS) involve intentionally exposing healthy volunteers to pathogens under controlled conditions. This research model aims to develop infection models, understand host-pathogen interactions, and test vaccines and therapeutics. CHIS accelerates research by providing crucial insights into disease mechanisms and immune responses.

### Why a CHIS facility in India?

India faces a significant burden of infectious diseases. The CHIS facility at THSTI's Medical Research Centre (MRC) offers a unique opportunity to study these diseases within a relevant local context. This will empower India to lead in generating data for disease prevention and treatment, accelerating the development of vaccines, diagnostics, and therapies.

#### Why THSTI?

THSTI's strong translational research foundation, multidisciplinary teams, ethical standards, and regulatory compliance make it ideal for operating this facility. The MRC's state-of-the-art infrastructure further supports the safety and research standards required for CHIS.

## Key research areas and focus

The facility will initially focus on prevalent diseases like influenza, typhoid, and expand to emerging infections and neglected tropical diseases. Research will address critical public health questions, including understanding immunity, identifying disease biomarkers, and accelerating vaccine efficacy studies.

## Innovative research capabilities

The CHIS facility aims to shorten clinical trial timelines, providing faster access to new interventions, particularly for diseases affecting low- and middle-income countries. It will also foster public-private collaborations and serve as a hub for high-quality infectious disease research in India.